Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224558 | 0.83 | MAP4K4 (0.57) | PIK3CAPLA2G1BATG4BKMT2AMAP4K4 | |
| SCHEMBL3458331 | 0.82 | ADORA2A (0.52) | ADORA2AADORA1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL28736380 | 0.82 | GRIN1 (0.46) | ADORA2AADORA1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL19721378 | 0.81 | KMT2A (0.47) | IKBKBHRH1HRH4IDO1HPGD | |
| SCHEMBL29857829 | 0.80 | CHEK2 (0.53) | HPGDMEN1MAPTKMT2AMAP4K4 | |
| SCHEMBL26917180 | 0.80 | CHEK2 (0.53) | HPGDMEN1MAPTKMT2AMAP4K4 | |
| SCHEMBL2559978 | 0.79 | ADORA2A (0.49) | ADORA2AADORA1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL15359055 | 0.77 | USP7 (0.60) | RAB9ASMN1; SMN2BRD4MEN1MAPT | |
| SCHEMBL29857982 | 0.77 | ADORA1 (0.49) | ADORA2AADORA1ATRMAPK1NPC1 | |
| SCHEMBL2226848 | 0.77 | FYN (0.54) | ADORA1PIK3CAPIK3CGKMT2AMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| CN-102812006-A | New anti-malarial agents | MEDICINES FOR MALARIA VENTURE MMV | 2012-12-05 | — | — | CN | disclosed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| CN-101384586-A | PI-3 kinase inhibitors and methods of use thereof | NOVARTIS AG (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | ADORA2A 914/4885ADORA1 1744/4885PIK3CD 2/4885 |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | QDPR, DHFR, ITPA | ADORA2A 567/4885ADORA1 120/4885PIK3CD 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.